Biotest Aktiengesellschaft (FRA:BIO)

FRA:BIO Statistics

Total Valuation

FRA:BIO has a market cap or net worth of EUR 1.33 billion. The enterprise value is 1.96 billion.

Market Cap	1.33B
Enterprise Value	1.96B

Important Dates

The next estimated earnings date is Monday, November 10, 2025.

Earnings Date	Nov 10, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	19.79M
Shares Outstanding	n/a
Shares Change (YoY)	-1.46%
Shares Change (QoQ)	+0.58%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.67%
Float	20.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	22.36
PS Ratio	2.09
PB Ratio	2.61
P/TBV Ratio	2.70
P/FCF Ratio	n/a
P/OCF Ratio	92.33
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 39.95, with an EV/FCF ratio of -136.82.

EV / Earnings	-79.86
EV / Sales	3.08
EV / EBITDA	39.95
EV / EBIT	257.43
EV / FCF	-136.82

Financial Position

The company has a current ratio of 4.93, with a Debt / Equity ratio of 1.31.

Current Ratio	4.93
Quick Ratio	1.49
Debt / Equity	1.31
Debt / EBITDA	12.53
Debt / FCF	-46.76
Interest Coverage	0.40

Financial Efficiency

Return on equity (ROE) is -4.72% and return on invested capital (ROIC) is 0.63%.

Return on Equity (ROE)	-4.72%
Return on Assets (ROA)	0.52%
Return on Invested Capital (ROIC)	0.63%
Return on Capital Employed (ROCE)	0.96%
Revenue Per Employee	254,589
Profits Per Employee	-9,820
Employee Count	2,495
Asset Turnover	0.44
Inventory Turnover	1.01

Taxes

Income Tax	-1.10M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +2.93% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+2.93%
50-Day Moving Average	42.03
200-Day Moving Average	41.21
Relative Strength Index (RSI)	50.21
Average Volume (20 Days)	2

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:BIO had revenue of EUR 635.20 million and -24.50 million in losses. Loss per share was -0.63.

Revenue	635.20M
Gross Profit	147.30M
Operating Income	12.00M
Pretax Income	-25.60M
Net Income	-24.50M
EBITDA	46.78M
EBIT	12.00M
Loss Per Share	-0.63

Balance Sheet

The company has 41.80 million in cash and 668.70 million in debt, giving a net cash position of -626.90 million.

Cash & Cash Equivalents	41.80M
Total Debt	668.70M
Net Cash	-626.90M
Net Cash Per Share	n/a
Equity (Book Value)	509.60M
Book Value Per Share	13.10
Working Capital	628.60M

Cash Flow

In the last 12 months, operating cash flow was 14.40 million and capital expenditures -28.70 million, giving a free cash flow of -14.30 million.

Operating Cash Flow	14.40M
Capital Expenditures	-28.70M
Free Cash Flow	-14.30M
FCF Per Share	n/a

Margins

Gross margin is 23.19%, with operating and profit margins of 1.89% and -3.86%.

Gross Margin	23.19%
Operating Margin	1.89%
Pretax Margin	-4.03%
Profit Margin	-3.86%
EBITDA Margin	7.36%
EBIT Margin	1.89%
FCF Margin	n/a

Dividends & Yields

FRA:BIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.46%
Shareholder Yield	1.46%
Earnings Yield	-1.84%
FCF Yield	-1.08%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 15, 2015. It was a forward split with a ratio of 3.

Last Split Date	Jul 15, 2015
Split Type	Forward
Split Ratio	3

Scores

FRA:BIO has an Altman Z-Score of 1.97 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.97
Piotroski F-Score	4